series-a
Stage
1
Investors
About
Adaptimmune develops engineered T-cell therapies to treat cancer by modifying immune cells to recognize and destroy cancer cells.
Explore Adaptimmune's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.